Afinitor 10 mg Tablets, manufactured by Novartis, is a globally trusted oral medication containing the active ingredient Everolimus. It is an innovative mTOR inhibitor specifically developed for the treatment of advanced cancers and other complex medical conditions. Afinitor 10 mg is a precision-targeted therapy designed to slow tumor growth, offering new hope to patients with breast cancer, kidney cancer, pancreatic neuroendocrine tumors (pNET), and tuberous sclerosis complex (TSC)-associated tumors.
Everolimus, the key component of Afinitor 10 mg, works by inhibiting the mammalian target of rapamycin (mTOR), a critical protein responsible for regulating cell growth, division, and survival. By blocking mTOR, Afinitor 10 mg disrupts cancer cell proliferation, reduces blood vessel formation (angiogenesis), and restricts the supply of nutrients essential for tumor growth. This triple-action mechanism makes Afinitor 10 mg a potent therapy across multiple cancer types and non-cancerous tumors.
🔬 Key Benefits & Indications of Afinitor 10 mg Everolimus:
- Breast Cancer: Afinitor 10 mg is approved in combination with hormonal therapy for HR-positive, HER2-negative advanced breast cancer in postmenopausal women.
- Renal Cell Carcinoma (RCC): Afinitor 10 mg is indicated for patients with advanced kidney cancer that has progressed after treatment with other targeted therapies.
- Pancreatic Neuroendocrine Tumors (pNET): Afinitor 10 mg slows the progression of rare pancreatic tumors that cannot be surgically removed.
- Tuberous Sclerosis Complex (TSC): Afinitor 10 mg is prescribed for TSC-associated renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA).
- Neuroendocrine Tumors (NET): Afinitor 10 mg is effective in non-functional gastrointestinal and lung neuroendocrine tumors.
💡 How Afinitor 10 mg Everolimus Works – Mechanism of Action:
- mTOR Inhibition: Afinitor 10 mg targets and blocks mTOR signaling, a pathway often overactive in cancer cells.
- Tumor Growth Suppression: It reduces protein synthesis and cell proliferation, leading to slowed tumor progression.
- Angiogenesis Inhibition: Afinitor 10 mg prevents the formation of new blood vessels that feed tumors, cutting off their nutrient supply.
- Immunomodulatory Effect: Everolimus modulates the immune response, offering additional therapeutic benefits in TSC and organ transplantation.
💊 Dosage & Administration of Afinitor 10 mg Everolimus:
- Standard Dose: 10 mg once daily, with or without food, taken at the same time each day.
- Dose Adjustments: Based on patient response and tolerability, dosage may be reduced to 5 mg daily.
- Swallow Whole: Do not crush, chew, or break the tablet.
⚠️ Side Effects of Afinitor 10 mg Everolimus:
- Fatigue and weakness.
- Stomatitis (mouth sores), inflammation of the mucosa.
- Nausea, diarrhea, and loss of appetite.
- Rash, skin irritation, or dryness.
- Elevated blood sugar levels (hyperglycemia).
- Infections and respiratory issues (cough, breathlessness).
- Rare but serious effects: Pneumonitis, renal failure, and liver toxicity.
🧊 Storage Instructions:
- Store Afinitor 10 mg tablets below 30°C, in a dry place.
- Keep in original packaging to protect from moisture and light.
- Keep out of reach of children.
🌍 Why Choose Afinitor 10 mg Everolimus by Novartis?
- mTOR Pathway Precision: Afinitor 10 mg is one of the pioneering therapies targeting mTOR, specifically designed to combat tumor growth.
- Multi-Cancer Application: Approved for breast cancer, kidney cancer, neuroendocrine tumors, and TSC-related growths.
- Oral Convenience: Once-daily oral administration offers ease compared to intravenous chemotherapy.
- Global Recognition: Approved by FDA, EMA, and other regulatory bodies, supported by extensive clinical research.
- Backed by Novartis: Produced by a globally trusted pharmaceutical giant known for oncology breakthroughs.
🏆 Clinical Trial Success:
- BOLERO-2 Trial: Afinitor 10 mg in combination with exemestane significantly extended progression-free survival in HR-positive, HER2-negative advanced breast cancer.
- RADIANT Trials: Demonstrated robust efficacy in neuroendocrine tumors and pancreatic tumors.
- RECORD Trials: Confirmed Afinitor’s effectiveness in renal cell carcinoma treatment.
Değerlendirmeler
Henüz değerlendirme yapılmadı.